Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503334 | 1.00 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL27812743 | 0.90 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL16141462 | 0.87 | SLC6A2 (0.73) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL12573083 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4302968 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4312521 | 0.85 | SLC6A2 (0.62) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL4310238 | 0.85 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL11639888 | 0.85 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4DRD2DRD1 | |
| SCHEMBL16141582 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL12573229 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2280955-B1 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | ALBANY MOLECULAR RES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9156812-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156812-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
| EP-2280955-A2 | CRYSTALLINE FORM OF 6-Ý(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL¨PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009149258-A2 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149259-A2 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | SLC6A2 121/4885SLC6A3 409/4885SLC6A4 28/4885 |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | SLC6A2 254/4885SLC6A3 459/4885SLC6A4 104/4885 |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | HTR2C, HTR3B, TPH2 | SLC6A2 217/4885SLC6A3 503/4885SLC6A4 112/4885 |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | SLC6A2 121/4885SLC6A3 409/4885SLC6A4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.